Mixed Reviews for A2AR Inhibitor in NSCLC.
Findings of a phase I/II trial of the adenosine 2A receptor blocker NIR178 combined with the PD-1 inhibitor spartalizumab in advanced non-small cell lung cancer suggest that the drugs are safe. Two of 25 patients showed complete or partial responses, and 13 had stable disease.